Dr. Alan B. Fleischer JR., MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Missouri, Columbia School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 509
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: University of Missouri, Columbia School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
OH license 35.133947 · KY license 48432 · NC license 33040
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Cincinnati Medical Center, LLC Cincinnati, OH
Medical groups
- University of Cincinnati Physicians Company LLC (1,506 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 509
- Services billed
- 2,032
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 745 | 154 |
| Established patient office or other outpatient visit, 30-39 minutes | 412 | 297 |
| Destruction of precancer skin growth, 1 growth | 274 | 208 |
| Established patient office or other outpatient visit, 20-29 minutes | 103 | 98 |
| Biopsy of related skin growth, first growth | 79 | 69 |
| Destruction of precancer skin growth, 15 or more growths | 27 | 20 |
| Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | 20 | 15 |
| Biopsy of related skin growth, each additional growth | 13 | 11 |
| New patient office or other outpatient visit, 45-59 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Humira(Cf) Pen (adalimumab) Other prescribers in Cincinnati, OH | 105 |
| Clobetasol Propionate Other prescribers in Cincinnati, OH | 104 |
| Dupixent Pen (dupilumab) Other prescribers in Cincinnati, OH | 102 |
| Triamcinolone Acetonide Other prescribers in Cincinnati, OH | 95 |
| Fluorouracil Other prescribers in Cincinnati, OH | 38 |
| Doxycycline Monohydrate Other prescribers in Cincinnati, OH | 35 |
| Ketoconazole Other prescribers in Cincinnati, OH | 30 |
| Doxycycline Hyclate Other prescribers in Cincinnati, OH | 30 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Cincinnati, OH | 24 |
| Fluocinonide Other prescribers in Cincinnati, OH | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $109 in total to this clinician.
| UCB, Inc. | $35.79 |
|---|---|
| AbbVie Inc. | $33.53 |
| Incyte Corporation | $24.80 |
| Novartis Pharmaceuticals Corporation | $14.64 |
| Food and Beverage | $109 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $134,809 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Incyte Corporation - A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation - A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis
Incyte Corporation - A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation - A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
UCB SA · Completed · NCT04901195
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.